Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine With or Without Trastuzumab in HER2+ Metastatic Breast Cancer Progressing After Trastuzumab
NCT00148876Phase 3Completed
- Sponsor
- GBG Forschungs
- Start
- Sep 2003
- Primary completion
- Jan 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab in breast cancer (2 arms), sponsored by GBG Forschungs. Primary endpoint: Time to Disease Progression. Started Sep 2003; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00148876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00148876.